POWAY, CA (PRWEB) AUGUST 27, 2015
The Kansas City Animal Health Investment Forum provides a unique opportunity for venture capital funds, investment firms and animal health companies to hear from animal health companies with the newest technology. Companies presenting at the Forum have raised $160 million. Several have also received licensing agreements or distribution contracts. This meeting is one of the only investment forums in the world dedicated to the animal health industry.
As a leader in stem cell science, Dr. Harman (CEO and Chief Science Officer) will present the pipeline progress highlighting the company's flagship canine osteoarthritis product in FDA development (expected approval 2017- 2018), as well as the future platform of development opportunities for which the company could utilize 'R&D acceleration funding'. VetStem's canine osteoarthritis product has already been commercially partnered with Aratana Therapeutics for development and distribution in the US markets.
"The opportunity to present to such a prestigious and influential group of investors and members of the veterinary industry is an honor and further recognition of the significant scientific and developmental progress we have achieved in recent years", stated Dr Harman.
"Our company de-risking process is truly unique. VetStem operates a central stem cell laboratory service where we can evaluate real stem cell efficacy rapidly in the field before entering the more expensive formal FDA development process. With 12 years of actual commercial stem cell therapy experience and over 11,000 animal patients treated through our service, we have a unique understanding of the real life challenges of bringing a novel product to market. This helps us both in the product development and the go-to-market strategies for those future products", added Dr Nahama (President and Chief Commercial Officer).
VetStem first pioneered stem cell therapy for use in horses for tendon injuries in 2003. Just two years after the first horse was treated, VetStem treated the first cat and dog. In 2007 the first peer reviewed, randomized, double-blinded, placebo controlled, multi-center study was published proving intra-articular injection of VetStem processed adipose derived stem cells in the hip joint of a dog decreased patient discomfort and increased patient functional ability. That same year VetStem brought to market the Genesis Platelet Rich Plasma concentration system, as well as the first formal small animal stem cell credentialing course for practicing veterinarians. In 2015, VetStem (now VetStem Biopharma) announced the successful completion of a pilot efficacy study for allogeneic stem cell therapy (93 dogs, multi-center, blinded, placebo controlled) in support of an FDA INAD. The study reached a successful primary efficacy end point and the complete study will be submitted for peer-reviewed publication later this year.
About VetStem Biopharma
VetStem Biopharma is a veterinarian lead company that was formed in 2002 to bring regenerative medicine to the profession. This privately held biopharmaceutical enterprise, based near San Diego (California), currently offers veterinarians an autologous stem cell processing service (from patients' own fat tissue) among other regenerative modalities. With a unique expertise acquired over the past 12 years and 11,000 patients treated by veterinarians for joint, tendon or ligament issues, VetStem has made regenerative medicine applications a therapeutic reality beyond the realm of research. The VetStem team is focused on developing new clinically practical and affordable veterinary solutions that leverage the natural restorative abilities present in all living creatures. The company's stated mission being "to extend and enhance the lives of animals by improving the quality of recovery in acute conditions, but also by unlocking ways to slow, stop and ultimately revert the course of chronic diseases". In addition to its' own portfolio of patents, Vet-Stem holds exclusive global veterinary licenses to a portfolio of over 55 issued patents in the field of regenerative medicine.